肝癌患者血清中lncRNA MIAT的表达及临床意义

Expression of IncRNA MIAT in serum of patients with hepatocellular carcinoma and its clinical significance

目的:检测肝细胞癌(hepatocellular carcinoma,HCC)患者血清中长链非编码RNA(long non-coding RNA,lncRNA)心肌梗死相关转录本(myocardial infraction association transcript,MIAT)的表达,并探讨其临床意义。方法:qRT-PCR法检测血清MIAT表达;ROC曲线分析其诊断HCC的价值;并研究MIAT表达与疾病进展及预后的关系。结果:MIAT在HCC患者血清中高表达,ROC曲线表明其表达可作为诊断HCC的血清标志物;与临床因素对比后发现MIAT表达与肿瘤数目、TNM分期和BCLC分期密切相关;对血清MIAT水平随访后发现其表达在肝癌肝切除术后降低,并在HCC复发时升高。结论:血清MIAT水平可作为诊断HCC的生物学标志物,其在评估HCC的恶性进展、手术疗效以及预测肿瘤复发方面具有潜在临床应用价值。

Objective:To detect the expression of Long non-coding RNA(lncRNA)myocardial infraction association transcript(MIAT)in serum of patients with hepatocellular carcinoma(HCC)and to explore its clinical significance.Methods:The expression of MIAT in serum of HCC patients was detected by qRT-PCR assay.The value of MIAT expression in the diagnosis of HCC was assessed by ROC curve,and the relationship between MIAT expression with HCC disease progression and prognosis was analyzed.Results:MIAT was highly expressed in serum of HCC patients,and ROC curve showed that MIAT expression could be used as a serum marker for diagnosis of HCC.MIAT expression was closely related to tumor number,TNM stage and BCLC stage.MIAT expression decreased after resection of HCC and increased when HCC recurred.Conclusion:Serum MIAT level can be used as a biomarker for the diagnosis of HCC.It has potential clinical value in evaluating the malignant progression and surgical efficacy of HCC as well as predicting recurrence of HCC.